<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004244</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067489</org_study_id>
    <secondary_id>CCF-IRB-3063</secondary_id>
    <secondary_id>NCI-T99-0028</secondary_id>
    <nct_id>NCT00004244</nct_id>
  </id_info>
  <brief_title>Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma</brief_title>
  <official_title>Phase I Trial of rhIL-12 and rHuIFN-a2b in Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of interleukin-12 and&#xD;
      interferon alfa in treating patients with metastatic kidney cancer or malignant melanoma.&#xD;
      Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a&#xD;
      person's white blood cells to kill cancer cells. Interferon alfa may interfere with the&#xD;
      growth of cancer cells. Combining interleukin-12 and interferon alfa may kill more cancer&#xD;
      cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the toxicity of interleukin-12 and interferon alfa in patients with metastatic&#xD;
      renal cell carcinoma or malignant melanoma.&#xD;
&#xD;
      II. Determine the maximum tolerated dose of these drugs when concurrently administered in&#xD;
      this patient population.&#xD;
&#xD;
      III. Obtain preliminary data on the antitumor efficacy of this combination in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study, followed by a randomized study.&#xD;
&#xD;
      Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three&#xD;
      times a week every week for 4 weeks. Treatment continues in the absence of unacceptable&#xD;
      toxicity or disease progression.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that&#xD;
      at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.&#xD;
&#xD;
      Once the MTD is established, additional patients are accrued and randomized to 1 of the&#xD;
      following treatment arms:&#xD;
&#xD;
      ARM I: Patients receive interleukin-12 SC twice a week for 2 weeks, followed by treatment&#xD;
      with interleukin-12 in combination with interferon alfa as described above.&#xD;
&#xD;
      ARM II: Patients receive interferon alfa SC three times a week for 2 weeks, followed by&#xD;
      treatment with interleukin-12 in combination with interferon alfa as described above.&#xD;
&#xD;
      ARM III: Patients receive treatment with interleukin-12 in combination with interferon alfa&#xD;
      at the MTD as described above.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for the dose escalation portion&#xD;
      of this study. An additional 18 patients (5 in arm I, 5 in arm II, and 8 in arm III) will be&#xD;
      accrued to the randomized portion of this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.&#xD;
Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.&#xD;
Patients receive interleukin-12 SC twice a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.&#xD;
Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.&#xD;
Patients receive interferon alfa SC three times a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.&#xD;
Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.&#xD;
Patients receive treatment with interleukin-12 in combination with interferon alfa at the MTD as described above.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interleukin-12</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed renal cell carcinoma or malignant melanoma&#xD;
&#xD;
          -  Strong clinical evidence or biopsy proof of metastases to a site or sites distant from&#xD;
             the primary tumor&#xD;
&#xD;
          -  Bidimensionally measurable of evaluable disease&#xD;
&#xD;
          -  No significant effusions and/or ascites&#xD;
&#xD;
          -  No more than 3 prior regimens for metastatic disease&#xD;
&#xD;
          -  No known CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.5 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  ALT/AST no greater than 3 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.8 mg/dL&#xD;
&#xD;
          -  Calcium no greater than 11.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of serious cardiac arrhythmia or cardiac arrhythmia requiring treatment&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No angina pectoris&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active peptic ulcer&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No local or systemic infections requiring IV antibiotics within the past 28 days&#xD;
&#xD;
          -  No known seizure disorder&#xD;
&#xD;
          -  No other prior malignancy except basal cell or squamous cell skin cancer, carcinoma in&#xD;
             situ of the cervix, or any curatively treated malignancy in complete remission for at&#xD;
             least 3 years&#xD;
&#xD;
          -  HIV, hepatitis B surface antigen, and hepatitis C negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Recovered from prior biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 28 days since prior hormonal therapy and recovered&#xD;
&#xD;
          -  No concurrent corticosteroids except for replacement steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy for control of pain from skeletal lesions&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 28 days since prior major surgery requiring general anesthesia&#xD;
&#xD;
          -  No organ allografts&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent aspirin&#xD;
&#xD;
          -  No concurrent barbiturates&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M. Bukowski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

